CDT Equity (CDT) Net Cash Flow (2022 - 2026)
CDT Equity's (CDT) quarterly Net Cash Flow came in at -$1.4 million in Q1 2026, down 188.27% YoY from $1.6 million in Q1 2025, and up 39.33% on a QoQ basis from -$2.3 million in Q4 2025.
CDT Equity (CDT) Net Cash Flow (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Net Cash Flow data on file, last reported at -$1.4 million in Q1 2026.
- Quarterly Net Cash Flow fell 188.27% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 534.45% YoY) and the FY2025 annual result came in at $1.1 million, up 128.95% from the prior year.
- Net Cash Flow grew to -$1.4 million in Q1 2026, from -$2.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $8.7 million in Q3 2023 to a low of -$4.7 million in Q4 2023.
- A 5-year average of $1411.8 and a median of -$21000.0 in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 1180.64% — and 2024, when it sank 34385.71%.
- Tracing CDT's Net Cash Flow over 5 years: stood at -$21000.0 in 2022, then plunged by 22361.9% to -$4.7 million in 2023, then soared by 110.88% to $513000.0 in 2024, then plunged by 552.05% to -$2.3 million in 2025, then jumped by 39.33% to -$1.4 million in 2026.
- The last three Net Cash Flow figures came in at -$1.4 million (Q1 2026), -$2.3 million (Q4 2025), and $599000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | -3.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.15 Mn |
| Jun 30, 2026 | -3.15 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Dec 31, 2025 | -2.32 Mn |
| Dec 31, 2025 | -2.32 Mn |
| Sep 30, 2025 | 599,000.00 |
| Sep 30, 2025 | 599,000.00 |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 513,000.00 |
| Dec 31, 2024 | 513,000.00 |
| Sep 30, 2024 | -160,000.00 |
| Sep 30, 2024 | -160,000.00 |
| Jun 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Mar 31, 2024 | -2.40 Mn |
| Mar 31, 2024 | -2.40 Mn |